NCT01319994View on ClinicalTrials.gov

Prevention of Metabolic Complications of Glucocorticoid Excess

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

January 31, 2015

Conditions
Iatrogenic Cushing Disease
Interventions
DRUG

Metformin

Metformin 850mg TDS (12 weeks)

DRUG

Placebo

Placebo 850mg TDS (12 weeks)

Trial Locations (1)

Unknown

Barts and the London, London

All Listed Sponsors
collaborator

Barts and the London School of Medicine and Dentistry

OTHER

lead

Barts & The London NHS Trust

OTHER

NCT01319994 - Prevention of Metabolic Complications of Glucocorticoid Excess | Biotech Hunter | Biotech Hunter